This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic
by Zacks Equity Research
QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.
QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.
Abbott Boosts Diagnostics Arm With Alinity H-Series Launch
by Zacks Equity Research
Abbott (ABT) adopts initiatives to strengthen hold in the high-potential diagnostics market.
QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.
QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View
by Zacks Equity Research
QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.
Should You Sell QIAGEN (QGEN) Before Earnings?
by Zacks Equity Research
QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.
Henry Schein Gains on Strategic Buyouts, Cost Concern a Woe
by Zacks Equity Research
Henry Schein (HSIC) continues to grow on dental and animal health business, thanks to merger and acquisition activity. However, rising costs continue to be a burden on the company's bottom line.
NuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive's (NUVA) latest receipt of expanded FDA 510(k) approval for PRECICE is likely to fortify its hold in the limb reconstruction and trauma market.
Abbott Banks on FDA Approvals and Buyouts, Competition Rife
by Zacks Equity Research
The market is upbeat about Abbott's (ABT) latest initiatives.
Bruker (BRKR) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
The new 52-week high of Bruker (BRKR) came on the back of several new initiatives, the most recent one being the introduction of the new CE-IVD marked Fungiplex Candida fast diagnostic assay.
LabCorp (LH) Strong on Strategic Planning, Competition Rife
by Zacks Equity Research
LabCorp (LH) grows on strong diagnostics business amid softness in the Covance drug development business.
Henry Schein Closes Merritt Buyout, Expands in Animal Health
by Zacks Equity Research
Henry Schein (HSIC) is consistently trying to expand its Animal Health business.
CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3
by Zacks Equity Research
CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.
QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife
by Zacks Equity Research
The market is upbeat about QIAGEN's (QGEN) partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio.
Is a Beat in Store for Abbott (ABT) This Earnings Season?
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre system receives back-to-back reimbursement approvals in several geographies, which are likely to drive growth in the Diabetes Care sales segment within Medical group.
QIAGEN Partners With CENTOGENE, Boosts Bioinformatics Suite
by Zacks Equity Research
QIAGEN (QGEN) makes another encouraging move to expand its advanced bioinformatics portfolio and add additional capabilities, partners CENTOGENE.
QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm
by Zacks Equity Research
QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.
Abbott-North West London Pathology Expand in Diagnostics
by Zacks Equity Research
Abbott Laboratories' (ABT) collaboration with North West London Pathology to strengthen its steadily growing diagnostics arm.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.
QIAGEN Strengthens Cancer Research Foothold on New License
by Zacks Equity Research
QIAGEN N.V. (QGEN) has received a worldwide license for biomarkers to be used in identifying patients who may have benefited from immune-oncology (I-O) therapies in cancer treatment.
Bristol-Myers Presents Data on Immuno-Oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers BMY announced that the EC has approved immuno-oncology drug Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy.
QIAGEN & Bristol-Myers Squibb Partner on Cancer Research
by Zacks Equity Research
QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.
Qiagen Banks on Molecular Diagnostic amid Currency Woes
by Zacks Equity Research
On May 4, we issued an updated research report on leading molecular diagnostic company, Qiagen N.V. (QGEN).
QIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported first-quarter 2017 adjusted earnings per share (considering restructuring expenses as one time item) of 22 cents, up 15.8% year over year.